Deepal V. Wakade
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
Journal: Melanoma research
Published: October 02, 2018
Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
Journal: The American Journal of dermatopathology
Published: January 04, 2017
Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
Journal: The Australasian journal of dermatology
Published: October 03, 2016
Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis.
Journal: Case reports in medicine
Published: August 19, 2016
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
Journal: Melanoma research
Published: April 01, 2016
Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Journal: Melanoma research
Published: April 01, 2016
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Journal: Journal of the American Academy of Dermatology
Published: July 24, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026